Inogen Inc
Inogen, Inc. (Nasdaq: INGN) develops, manufactures, and markets respiratory health products, primarily portable oxygen concentrators for patients needing long-term oxygen therapy. Its Inogen One and Inogen Rove systems provide supplemental oxygen for use at home and on the go, while its Inogen At Home and Voxi 5… From the company’s description.
Over the twelve months to Jun 30, 2026, Inogen Inc reported revenue of $354.30M, up 3.2% from a year earlier, and a net loss of $24.59M. Its operating margin was −8.7%, and operations used $2.52M in cash. In fiscal 2025, it reported revenue of $348.67M, up 3.9% from fiscal 2024, and a net loss of $22.75M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Inogen Inc does
In the company’s own words
Inogen, Inc. (Nasdaq: INGN) develops, manufactures, and markets respiratory health products, primarily portable oxygen concentrators for patients needing long-term oxygen therapy. Its Inogen One and Inogen Rove systems provide supplemental oxygen for use at home and on the go, while its Inogen At Home and Voxi 5 concentrators provide stationary oxygen therapy. The company also sells Simeox airway-clearance devices for patients who need help removing lung mucus, and Aurora CPAP masks for patients with obstructive sleep apnea. Customers include patients purchasing or renting products directly, home medical equipment providers, distributors, resellers, and international house accounts such as gas companies and home oxygen providers. In the United States, sales include direct-to-consumer purchases and rentals, as well as sales to business customers; internationally, products are sold in 70 countries through distributors, resellers, and direct accounts. U.S. revenue was $209.8 million in 2025. The portfolio expanded through the 2023 acquisition of Physio-Assist, which developed Simeox, and a 2025 collaboration with Yuwell that brought Voxi 5 and Aurora masks to the U.S. market.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- BEVERLY, MA
- Fiscal year end
- December
- CIK
- 1294133
- SIC
- 3842
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Inogen Inc — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Inogen Inc’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Inogen Inc and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Inogen Inc's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Inogen Inc's last four quarterly filings that the numbers alone won't show?”